

Financial news for PBYI dated on 2020-05-20: Cantor Fitzgerald Maintains Neutral on Puma Biotechnology, Raises Price Target to \$16

Financial news for PBYI dated on 2020-05-08: Puma Biotechnology shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for PBYI dated on 2020-05-07: Puma Biotechnology Q1 Adj. EPS \$(0.200) Beats \$(0.730) Estimate, Sales \$48.600M Beat \$47.060M Estimate

Financial news for PBYI dated on 2020-05-07: Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval In Mainland China For NERLYNX For Extended Adjuvant Treatment Of Early Stage HER2-Positive Breast Cancer

Financial news for PBYI dated on 2020-04-30: UPDATE: Puma Biotech Says Will Receive Upfront, Milestone Payments Of Up To \$6M

Financial news for PBYI dated on 2020-04-30: Puma Biotech Reports Exclusive License Deal With Bixink Therapeutics For Commercialization Of NERLYNX (Neratinib) In South Korea

Financial news for PBYI dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for PBYI dated on 2020-02-26: Puma Biotech Reports FDA Approval Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

Financial news for PBYI dated on 2020-02-21: Puma Biotechnology shares are trading lower after the company reported worse-than-expected Q4 sales results.

Financial news for PBYI dated on 2020-02-20: Puma Biotechnology Q4 EPS \$0.01, Sales \$58.7M Miss \$59.96M Estimate

Financial news for PBYI dated on 2020-01-16: Puma Biotechnology shares are trading higher following yesterday's presentation at the JP Morgan Healthcare Conference.

Financial news for PBYI dated on 2020-01-14: Puma Biotechnology shares are trading higher ahead of the company's Wednesday presentation at the JP Morgan Healthcare Conference. At the conference, the company will provide an update and highlight preliminary NERLYNX sales for Q4.

Financial news for PBYI dated on 2019-12-16: Puma Biotechnology shares are trading lower after the company presented interim results for its Phase 2 clinical trial of Neratinib.

Financial news for PBYI dated on 2019-12-13: Puma Biotechnologies shares are trading higher on continued momentum after the company reported data on its Nerlynx for breast cancer patients.

Financial news for PBYI dated on 2019-12-12: Puma Biotech Shares Relatively Quiet Following Press Release Highlighting Collaborators At The Institute Of Cancer Research, London Presented Results From Cohort Of Patients In plasmaMATCH Trial Treated With Co.'s Neratinib At SABCS

Financial news for PBYI dated on 2019-12-10: Puma Biotechnology shares are trading higher. Not seeing any news to justify the price action.

Financial news for PBYI dated on 2019-12-06: H.C. Wainwright Initiates Coverage On Puma Biotechnology with Buy Rating, Announces \$15 Price Target

Financial news for PBYI dated on 2019-12-05: Puma Biotechnology shares are trading lower. Not seeing any news to justify the price action. NOTE: The stock has dropped approximately 25% over the past 3 trading sessions.

Financial news for PBYI dated on 2019-12-02: Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval In Singapore For NERLYNX For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

Financial news for PBYI dated on 2019-12-02: Puma Biotechnology shares are trading higher after the company extended its commercialization agreement with Pierre Fabre for NERLYNX to the Middle East, South Africa, Sudan, and Turkey.

Financial news for PBYI dated on 2019-12-02: Puma Biotechnology Extends its Commercialization Agreement with Pierre Fabre for NERLYNX to the Middle East, South Africa, Sudan and Turkey

Financial news for PBYI dated on 2019-11-14: Puma Biotechnology shares are trading lower on seemingly no company-specific news.

Financial news for PBYI dated on 2019-11-08: Puma Biotechnology shares are trading higher on continued momentum after the company reported better-than-expected Q3 EPS results.

Financial news for PBYI dated on 2019-11-06: Puma Biotechnology Q3 EPS \$(0.44) Beats \$(0.71) Estimate, Sales \$56.4M Miss \$60.4M Estimate

Financial news for PBYI dated on 2019-11-05: Puma Biotech Reports Its Licensing Partner, CANbridge Pharma, Receives Registration Approval In Hong Kong For NERLYNX

Financial news for PBYI dated on 2019-10-08: UPDATE: Goldman On Puma Biotechnology Also Notes 'We believe that even if tucatinib is not differentiated on efficacy, it may garner more market share on greater tolerability based on mCRC data shown at ESMO'

Financial news for PBYI dated on 2019-10-08: UPDATE: Goldman Downgrades Puma Biotechnology To Sell, Lowers Target To \$8 As Firm Notes 'we think the headline risk from upcoming competitive data at YE2019 from SGEN's tucatinib (link) is underappreciated and creates a challenging set up'

Financial news for PBYI dated on 2019-10-08: Puma Biotechnology shares are trading lower after Goldman Sachs downgraded the company's stock from Neutral to Sell and lowered the price target from \$24 to \$8.

Financial news for PBYI dated on 2019-10-08: Goldman Sachs Downgrades Puma Biotechnology to Sell, Lowers Price Target to \$8

Financial news for PBYI dated on 2019-10-02: Puma Biotech Reports FDA Approved Labeling Supplement For Co.'s NERLYNX For Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2019-09-11: Puma Biotechnology Announces FDA Acceptance Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer

Financial news for PBYI dated on 2019-09-04: Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization For NERLYNX For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer

Financial news for PBYI dated on 2019-09-03: Puma Biotech shares are trading higher after the FDA granted Orphan Drug Designation to NERLYNX for the treatment of breast cancer patients with brain metastases.

Financial news for PBYI dated on 2019-09-03: Puma Biotech Reports FDA Granted Orphan Drug Designation For Co.'s NERLYNX For Treatment Of Breast Cancer Patients With Brain Metastases

Financial news for PBYI dated on 2019-08-09: Barclays Maintains Underweight on Puma Biotechnology, Lowers Price Target to \$9

Financial news for PBYI dated on 2019-08-09: Puma Biotechnology shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for PBYI dated on 2019-08-08: Puma Biotechnology shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for PBYI dated on 2019-08-08: Puma Biotechnology Q2 EPS \$(0.97) Beats \$(1) Estimate, Sales \$53.9M Beat \$52.98M Estimate

Financial news for PBYI dated on 2019-07-26: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., July 26, 2019

Financial news for PBYI dated on 2019-07-16: Puma Biotech Highlights Its Licensing Partner Knight Therapeutics Received Regulatory Approval From Health Canada Related To Commercialization Of NERLYNX For HER2-Positive Early-Stage Breast Cancer

Financial news for PBYI dated on 2019-07-03: Puma Biotech Highlights Presentation Of Interim Results From Biliary Tract Cohort At World Congress On Gastrointestinal Cancer

Financial news for PBYI dated on 2019-07-01: Puma Biotechnology Submits a Supplemental New Drug Application to the US FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

Financial news for PBYI dated on 2019-06-14: Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., June 14, 2019

Financial news for PBYI dated on 2019-06-13: Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Thur., June 13, 2019

Financial news for PBYI dated on 2019-06-04: Puma Biotechnology Highlights Presentation Of Results From Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer At ASCO 2019 Annual Meeting

Financial news for PBYI dated on 2019-05-10: Puma Biotechnology shares are trading lower after the company reported its Q1 Nerlynx sales declined from the previous quarter due to patients discontinuing treatment. Cantor Fitzgerald downgraded the stock from Overweight to Neutral.

Financial news for PBYI dated on 2019-05-10: Citi Downgrades Puma Biotechnology Inc - Common Stock to Neutral, Announces \$24 Price Target

Financial news for PBYI dated on 2019-05-10: Cantor Fitzgerald Downgrades Puma Biotechnology Inc - Common Stock to Neutral, Lowers Price Target to \$20

Financial news for PBYI dated on 2019-05-09: Puma Biotechnology shares are trading lower after the company reported Q1 Nerlynx sales decline from last quarter due to an increase in patients discontinuing treatment.

Financial news for PBYI dated on 2019-05-09: Puma Biotechnology Reports Q1 Nerlynx Sales Declined From Last Quarter Due To An Increase In Patients Discontinuing Treatment

Financial news for PBYI dated on 2019-05-09: Puma Biotechnology Q1 EPS \$(0.26) Beats \$(0.68) Estimate, Sales \$99.1M Beat \$67.25M Estimate

Financial news for PBYI dated on 2019-05-06: Alterity Therapeutics Highlights Initial Data Presented At American Academy of Neurology Annual Meeting

Financial news for PBYI dated on 2019-04-04: Puma Biotech Reports Expansion Of Cohorts In Phase II SUMMIT Trial Of Neratinib In Cancer Patients With Tumors With Activating EGFR, HER2 Mutations

Financial news for PBYI dated on 2019-04-01: Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX in Europe

Financial news for PBYI dated on 2019-03-28: Puma Biotech Highlights Publication Of 12 Abstracts On Neratinib For AACR Annual Meeting 2019

Financial news for PBYI dated on 2019-03-18: From Earlier: Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval To Commercialize NERLYNX For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2019-03-01: Puma Biotechnology shares are trading higher after the company reported better-than-expected Q4 EPS and sales estimates; the company also reported a 204% year-over-year increase in sales of its NERLYNX breast cancer treatment.

Financial news for PBYI dated on 2019-02-28: Puma Biotechnology Q4 EPS \$(0.32) Beats \$(0.77) Estimate, Sales \$71.1M Beat \$53.65M Estimate

Financial news for PBYI dated on 2019-02-15: Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage

Financial news for PBYI dated on 2019-01-17: Leerink Swann Initiates Coverage On Puma Biotechnology with Market Perform Rating

Financial news for PBYI dated on 2019-01-11: Puma Biotechnology Enters Into An Exclusive License Agreement With Knight Therapeutics That Grants Knight The Exclusive Right To commercialize NERLYNX (neratinib) In Canada

Financial news for PBYI dated on 2019-01-03: Guggenheim Downgrades Puma Biotechnology to Neutral

Financial news for PBYI dated on 2018-12-17: Puma Biotechnology shares are trading higher after the company reported favorable results from its Phase III NALA trial of Neratinib in breast cancer patients.

Financial news for PBYI dated on 2018-12-17: Puma Biotechnology Says top Line Results From Phase III NALA Trial Of Neratinib In Breast Cancer Patients Resulted In Statistically Significant Improvement In Centrally Confirmed Progression Free Survival; Safety Profile Consistent With Previous Trials

Financial news for PBYI dated on 2018-12-06: Puma Biotech Offers Results Of Patient-Reported Outcomes In Phase II CONTROL Trial Of Neratinib In Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer At San Antonio Breast Cancer Symposium

Financial news for PBYI dated on 2018-11-19: Goldman Sachs Upgrades Puma Biotechnology to Neutral, Lowers Price Target to \$28

Financial news for PBYI dated on 2018-11-02: JP Morgan Maintains Underweight on Puma Biotechnology, Lowers Price Target to \$23

Financial news for PBYI dated on 2018-11-02: JP Morgan Earlier On Puma Biotech: Sees Shares Underperforming Firm's Coverage Universe Until Evidence Of Sustained Commercial Momentum Is Apparent

Financial news for PBYI dated on 2018-11-02: Cantor Fitzgerald Maintains Overweight on Puma Biotechnology, Lowers Price Target to \$50

Financial news for PBYI dated on 2018-11-02: Barclays Downgrades Puma Biotechnology to Underweight, Lowers Price Target to \$29

Financial news for PBYI dated on 2018-11-02: JP Morgan Downgrades Puma Biotechnology to Underweight, Lowers Price Target to \$23

Financial news for PBYI dated on 2018-11-01: Puma Biotechnology shares are trading lower after the company's Nerlynx sales were lower than expected.

Financial news for PBYI dated on 2018-11-01: Puma Biotechnology Q3 Adj. EPS \$0.17 Beats \$(0.97) Estimate, Sales \$52.6M Miss \$57.94M Estimate

Financial news for PBYI dated on 2018-11-01: Stocks Which Set New 52-Week Low Yesterday, October 31st

Financial news for PBYI dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for PBYI dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for PBYI dated on 2018-10-16: Celcuity Announces Clinical Trial Collaboration With Puma Biotechnology And West Cancer Center

Financial news for PBYI dated on 2018-10-02: Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application For NERLYNX (neratinib) In China

Financial news for PBYI dated on 2018-10-01: Cantor Fitzgerald Initiates Coverage On Puma Biotechnology with Overweight Rating, Announces \$75 Price Target

Financial news for PBYI dated on 2018-09-18: Citigroup Maintains Buy on Puma Biotechnology, Lowers Price Target to \$151

Financial news for PBYI dated on 2018-09-17: Goldman Sachs Initiates Coverage On Puma Biotechnology with Sell Rating, Announces \$42 Price Target

Financial news for PBYI dated on 2018-09-04: European Commission Grants Marketing Authorisation To Puma Biotechnology's NERLYNX For Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2018-08-10: Puma Biotechnology shares are up 11.6% premarket after the company beat Q2 earnings estimates.

Financial news for PBYI dated on 2018-08-09: Puma Biotechnology Q2 EPS \$(0.59) Beats \$(1.26) Estimate, Sales \$50.8M Beat \$45.67M Estimate

Financial news for PBYI dated on 2018-08-09: Stocks Which Set New 52-Week Low Yesterday, August 8th

Financial news for PBYI dated on 2018-08-08: Stocks Which Set New 52-Week Low Yesterday, August 7th

Financial news for PBYI dated on 2018-08-01: Stocks Which Set New 52-Week Low Yesterday, July 31

Financial news for PBYI dated on 2018-07-31: Puma Biotechnology Files New Drug Submission For NERLYNX For Breast Cancer In Canada

Financial news for PBYI dated on 2018-07-17: Puma Biotechnology Announces Collaboration With Strata Oncology To Accelerate Enrollment In Phase II SUMMIT trial

Of PB272; SUMMIT Trial Evaluates Safety And Efficacy Of Neratinib In Patients With Solid Tumors With Mutations

Financial news for PBYI dated on 2018-06-29: Puma Biotech Reports Received Positive CHMP Opinion Related To Approval Of NERLYNX For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2018-06-28: Citigroup Maintains Buy on Puma Biotechnology, Raises Price Target to \$164

Financial news for PBYI dated on 2018-06-26: Puma Biotech Shares Resume Trade, Up 31.7%

Financial news for PBYI dated on 2018-06-26: Puma Biotech Shares To Resume Trade At 9:15 a.m. EDT

Financial news for PBYI dated on 2018-06-26: Puma Biotech Reports Results Of CHMP Reexamination Of MAA For Neratinib For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer: Recommended Approval

Financial news for PBYI dated on 2018-06-26: Puma Biotech Shares Halted News Pending

Financial news for PBYI dated on 2018-06-18: Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

Financial news for PBYI dated on 2018-06-14: Puma Biotechnology Option Alert: Jul 20 \$60 Calls at the Ask: 5000 @ \$1.7 vs 1402 OI; Earnings 8/8 After Close [est] Ref=\$52.3

Financial news for PBYI dated on 2018-06-07: Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma

Financial news for PBYI dated on 2018-05-10: Puma Biotech Shares Down 17% For Session; Hearing Citi Issued Mid-Day Defense On Name, Called Selloff Overdone

Financial news for PBYI dated on 2018-05-09: Puma Biotechnology Q1 Adj. EPS \$0.03 Beats \$(1) Estimate, Sales \$66.5M Beat \$58.5M Estimate

Financial news for PBYI dated on 2018-04-12: Barclays Downgrades Puma Biotechnology to Equal-Weight

Financial news for PBYI dated on 2018-04-03: Puma Biotech, Pint Pharma Report Exclusive Licensing Deal To Commercialize Neratinib In Latin America

Financial news for PBYI dated on 2018-04-02: Puma Biotechnology Announces that NERLYNX Has Been Included as a Treatment Option in the National Comprehensive Cancer Network

Financial news for PBYI dated on 2018-03-02: Barclays Maintains Overweight on Puma Biotechnology, Lowers Price Target to \$90.00

Financial news for PBYI dated on 2018-03-01: Puma Biotechnology Reports Q4 Adj. EPS \$(1.03) vs \$(1.98) Est., Sales \$20.1M vs \$20.0M Est.

Financial news for PBYI dated on 2018-02-23: Puma Biotech Shares Quiet Premarket Following EMA Recommendation Against Approval Of Co.'s Neratinib

Financial news for PBYI dated on 2018-02-14: Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma

Financial news for PBYI dated on 2018-02-01: Puma Biotechnology, CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX In China; Puma To Receive \$30M Upfront And \$40M In Potential Milestone Payments

Financial news for PBYI dated on 2018-01-31: Puma Biotech Reports Publication Of Results From Phase II SUMMIT Basket Trial On Neratinib In HER2, HER3 Mutant Cancers

Financial news for PBYI dated on 2018-01-30: Puma Biotech Shares Ticking Modestly Lower As Traders Circulating FDA.gov Alert 'FDA limits packaging for anti-diarrhea medicine Loperamide (Imodium) to encourage safe use'

Financial news for PBYI dated on 2018-01-30: Puma Biotechnology, Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX

Financial news for PBYI dated on 2018-01-24: Puma Biotech Shares Down 26.73% On

Earlier Cowen Downgrade, Subsequent STAT News' Adam F Twitter Mention

Financial news for PBYI dated on 2018-01-24: Cowen & Co. Downgrades Puma Biotechnology to Market Perform

Financial news for PBYI dated on 2018-01-23: UPDATE: Puma Says Negative Trend Vote Means 'additional steps would need to be taken to gain marketing approval in Europe'

Financial news for PBYI dated on 2018-01-23: Puma Biotech Reports EMA's CHMP Communicated Negative Trend Vote After Meeting To Discuss MAA For Neratinib

Financial news for PBYI dated on 2018-01-11: Puma Biotech 8-K Shows, Based On CHMP SAG Opinion, Co. 'intends to modify the SmPC...in its MAA for neratinib to further refine the intended population to patients at a high risk of disease recurrence'

Financial news for PBYI dated on 2018-01-05: Adam Feuerstein Tweets: \$PBYI is not presenting at #JPM18 but before your M&A hearts get all a-flutter, it's because they're in Europe for an EMA meeting related to the Nerlynx review.

Financial news for PBYI dated on 2018-01-03: Puma Biotechnology Shares Up 3.18%; Bank Of America Out Defending, Says Stock Selloff On FDA's FAERS Death Reports Overdone, Says Unconcerned About Safety Of Nerlynx Treatment And Maintains Buy Rating

Financial news for PBYI dated on 2017-12-13: Puma Biotech Reports EMA Requested Scientific Advisory Group On Oncology Provide Opinion On Clinical Aspects Of MAA For Neratinib At Jan. 11 Meeting

Financial news for PBYI dated on 2017-12-12: Puma Biotech, Daiichi Sankyo Report Research Collaboration With Major Cancer Center In HER2-Mutated Cancer

Financial news for PBYI dated on 2017-12-11: Puma Biotechnology Announces Patent Claims for Extended Adjuvant Treatment Upheld

Financial news for PBYI dated on 2017-12-06: Puma Biotech Will Present Updated Interim Results From Phase II CONTROL Trial Of Neratinib Dec. 7 6pm ET At San Antonio Breast Cancer Symposium

Financial news for PBYI dated on 2017-11-22: UPDATE: Puma Says Will Receive Upfront, Milestone Payments Of Up to \$4.5M Throughout Term Of NERLYNX Commercialize Deal

Financial news for PBYI dated on 2017-11-22: Puma Biotech, Specialised Therapeutics Asia Report Entered Into Exclusive Licensing Deal To Commercialize NERLYNX In Australia, New Zealand, South East Asia

Financial news for PBYI dated on 2017-11-15: Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics

Financial news for PBYI dated on 2017-11-10: Barclays Maintains Overweight on Puma Biotechnology, Raises Price Target to \$122.00

Financial news for PBYI dated on 2017-11-10: Credit Suisse Maintains Outperform on Puma Biotechnology, Raises Price Target to \$142.00

Financial news for PBYI dated on 2017-11-09: Puma Biotechnology Reports Q3 Adj. EPS \$(1.36) vs \$(2.49) Est., Sales \$6.1M vs \$3.74M Est.

Financial news for PBYI dated on 2017-11-07: Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead

Financial news for PBYI dated on 2017-11-02: Puma Biotechnology Secures \$100M Term Loan from Silicon Valley Bank and Oxford Finance

Financial news for PBYI dated on 2017-10-05: Citi Raises Target On Puma Biotech To \$156, Reiterates Co. As Acquisition Target

Financial news for PBYI dated on 2017-09-26: Cantor Fitzgerald Global Healthcare Conference Continues Today, Presenters Include: Innoviva, Puma Biotech, Magellan Health, TherapeuticsMD, Zoetis, Aurinia Pharma and Celgene

Financial news for PBYI dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for PBYI dated on 2017-09-08: Puma Biotech Reports Presentation Of 5-Year Analysis Of Phase III ExteNET Trial In Extended Adjuvant HER2-Positive Breast Cancer: Showed 'Continued Benefit from Neratinib after 5 years'

Financial news for PBYI dated on 2017-09-07: Barclays Initiates Coverage On Puma Biotechnology with Overweight Rating, Announces \$103.00 Price Target

Financial news for PBYI dated on 2017-09-06: Citi Biotech Conference Begins Today, Presenters Include: Gilead, Ligand, Puma Biotech, and Bioverativ

Financial news for PBYI dated on 2017-08-09: Puma Biotech Reports Q2 Adj. EPS \$(1.38) vs \$(2.04) Est.

Financial news for PBYI dated on 2017-08-02: Puma Biotech Reports Received Day-180 List Of Outstanding Issues From Committee For Medicinal Products For Human Use

Financial news for PBYI dated on 2017-08-01: Leerink Out Defending Puma Biotechnology, Says Shares Are Underperforming On Company News That Nerlyx Is Now Commercially Available By Prescription In U.S.; Believes Weakness In Shares Provides Buying Opportunity And Reiterates Outperform Rating

Financial news for PBYI dated on 2017-07-31: Puma Biotech Announces NERLYNX Now Commercially Available

Financial news for PBYI dated on 2017-07-18: Puma Biotech Shares Up 8% In Pre-Market Following FDA Approval Of NERLYNX On Monday

Financial news for PBYI dated on 2017-07-17: Puma Biotech Shares Resume Trading, Now Up 10.34% After-Hours

Financial news for PBYI dated on 2017-07-17: Puma Biotech Shares Resume Trading At 5:55pm ET

Financial news for PBYI dated on 2017-07-17: Puma Biotech Reports FDA Approval Of NERLYNX For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2017-07-17: Traders Circulating Doc From FDA Suggesting Puma Biotech Received Approval For Its Breast Cancer Treatment NERLYNX

Financial news for PBYI dated on 2017-07-17: Puma Biotech Shares Halted News Pending

Financial news for PBYI dated on 2017-07-10: Leerink Swann Reinstates Outperform on Puma Biotechnology, Announces \$115.00

Financial news for PBYI dated on 2017-07-06: Puma Biotech Completes Targeted Enrollment In Neratinib Phase III Trial, Expects Primary Analysis Available First Half 2018

Financial news for PBYI dated on 2017-06-07: Jefferies Health Care Conference Continues Today, Presenters Include Teva, WAVE Life Sciences, Envision Healthcare, NantKwest, Ignyta, Puma Biotech, and Kite Pharma

Financial news for PBYI dated on 2017-06-05: 13G Filing Shows Partner Fund Reporting 8% Stake In Puma Biotech

Financial news for PBYI dated on 2017-05-25: Cowen & Co. Upgrades Puma Biotechnology to Outperform

Financial news for PBYI dated on 2017-05-24: Puma Biotech Shares Tick Slightly Higher Over Last Few Mins as Stifel Raises Price Target to New Street High at \$105

Financial news for PBYI dated on 2017-05-24: Puma Biotech Shares Resume Trade, Now Up 22-23%

Financial news for PBYI dated on 2017-05-24: Puma Biotech Shares to Resume Trade at 1:50 p.m. EDT

Financial news for PBYI dated on 2017-05-24: Puma Release Confirms Co.'s Neratinib Received FDA Panel Support

Financial news for PBYI dated on 2017-05-24: Adam Feuerstein Tweets: Congrats to those who supported \$PBYI & neratinib's approval in extended adjuvant breast. You were right. I did not and I was wrong.

Financial news for PBYI dated on 2017-05-24: CNBC's Meg Tirrell Tweets '\$PBYI vote - risk/ben support treatment? Yes: 12 No: 4 Abstain: 0'

Financial news for PBYI dated on 2017-05-24: CNBC's Meg Tirrell Tweets 'Another FDA panel member weighing in on concerns about broadness of \$PBYI indication before vote'

Financial news for PBYI dated on 2017-05-24: Adam Feuerstein Tweets: \$PBYI panel moving to discussion and voting. Live blog here --> thestreet.com/story/14146508

Financial news for PBYI dated on 2017-05-24: Adam Feuerstein Tweets: \$PBYI panel break. Some more pointed concerns at end of Q&A but still going company's way, overall.

Financial news for PBYI dated on 2017-05-24: TheStreet's Adam Feuerstein Tweets '\$PBYI panel is sorta boring so far, which probably works in its favor.'

Financial news for PBYI dated on 2017-05-24: TheStreet's Adam Feuerstein Tweets '\$PBYI presenting neratinib data at FDA panel. Follow here -->'

Financial news for PBYI dated on 2017-05-23: Adam Feuerstein Tweets: Re: \$PBYI FDA panel. I'm interested in hearing from expert Dr. Hal Burstein. In '15, he called neratinib "awful." thestreet.com/story/13170389...

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Resumed Following Third Circuit Breaker Halt, Now Up 38.7%

Financial news for PBYI dated on 2017-05-22: Forbes Reporter Matthew Herper Tweets: ..the recommendation not to file and the multiple trial amendments could be a real problem. If study became biased, that hurts \$PBYI.

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares to Resume Trade at 10:27:11 a.m. EDT Following Third Circuit Breaker Halt

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Halted on a Circuit Breaker to the Downside, Still Up ~51.5% for Session

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Resume Trade, Ticks Slightly Lower, Now Up 79% for Session

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares to Resume Trade at 10:14:51 a.m. EDT

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Now Up 83.5%, Around \$69.35 Level; Halted on Third Circuit Breaker

Financial news for PBYI dated on 2017-05-22: TheStreet's Adam Feuerstein Tweets 'For \$PBYI bears, this ? from FDA: "totality of evidence of neratinib's efficacy data in context of other approvals in the adjuvant setting/"'

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Resume, Continue Higher, Now Up 58%

Financial news for PBYI dated on 2017-05-22: Adam Feuerstein Tweets: \$PBYI FDA review of neratinib played straight. No "OMG" landmines. Efficacy supportive, safety a concern. This is win for bulls. On to Weds.

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares to Resume Trade Following Second Circuit Breaker at 10:03:03 a.m. EDT

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Resume, Now Up 45.5%; Halted on Second Circuit Breaker

Financial news for PBYI dated on 2017-05-22: UPDATE: Puma Biotech Briefing Docs Show Study 3004 Met Prespecified Primary Efficacy Endpoint, Showed Statistically Significant Improvement of iDFS in Patients Treated with Neratinib vs Placebo

Financial news for PBYI dated on 2017-05-22: Puma Biotech Ad. Comm. Documents Shows neratinib Performed Better Than Roche's trastuzumab In I-SPY2 Trial, Particularly In Subgroup Of Patients That Were HRC Negative

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares to Resume Trade at 9:57:33 a.m. EDT

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Spike Into Positive Territory, Now Up 9%; Halted on Circuit Breaker

Financial news for PBYI dated on 2017-05-22: Puma Biotech Shares Spiking Higher As Briefing Documents For Wed. Ad Comm. Meeting Are Published To FDA

Financial news for PBYI dated on 2017-05-16: Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics

Financial news for PBYI dated on 2017-05-10: Puma Biotech Reports Q1 Adj. EPS \$(1.16) vs \$(1.98) Est.

Financial news for PBYI dated on 2017-05-05: Adam Feuerstein Tweets: \$PBYI CEO Alan

Auerbach can end speculation by filing 8-K declaring Puma has not received the FDA briefing book on neratinib.

Financial news for PBYI dated on 2017-04-18: Adam Fuerstein Tweets: Shortened FDA Advisory Panel is Bad Omen for \$PBYI Controversial Breast Cancer Drug

Financial news for PBYI dated on 2017-04-17: Puma Biotech Reports FDA Advisory Committee to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2017-04-12: Caligor Opco To Support Puma Biotechnology Expanded Access Program For PB272 In U.S.

Financial news for PBYI dated on 2017-04-04: UPDATE: 95.4% Of Puma's ExteNET Patients Experienced A Form of Diarrhea Ranked From Level 1 To 4 Grade

Financial news for PBYI dated on 2017-04-04: Puma Biotechnology Says 39.8% Of ExteNET Patients Experienced Grade 3 or Higher Diarrhea In HER2-Positive Early Stage Breast Cancer

Financial news for PBYI dated on 2017-03-02: Adam Feuerstein Tweets: Hedge funds that own \$PBYI are screaming at sell side analysts to defend the stock, per my sources.

Financial news for PBYI dated on 2017-03-01: Puma Biotechnology To Modify Summary Of Product Characteristics To Restrict Intended Population To Patients Initiating Treatment Within On Year After Completion Of Adjuvant trastuzumab Patients

Financial news for PBYI dated on 2017-03-01: Puma Biotechnology Reports Q4 Adj. EPS \$(1.22) vs \$(1.92) Est.

Financial news for PBYI dated on 2017-02-15: Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma

Financial news for PBYI dated on 2016-09-21: Stifel Nicolaus Upgrades Puma Biotechnology to Buy

Financial news for PBYI dated on 2016-09-21: Stifel Nicolaus Upgrades Puma Biotechnology to Buy

Financial news for PBYI dated on 2016-03-29: Credit Suisse Maintains Outperform on Puma Biotechnology, Lowers PT to \$50.00

Financial news for PBYI dated on 2016-03-29: RBC Capital Downgrades Puma Biotechnology to Sector Perform, Lowers PT to \$36.00

Financial news for PBYI dated on 2016-03-29: JP Morgan Maintains Overweight on Puma Biotechnology, Lowers PT to \$89.00

Financial news for PBYI dated on 2016-03-29: Citigroup Maintains Buy on Puma Biotechnology, Lowers PT to \$88.00

Financial news for PBYI dated on 2016-02-11: Earlier Credit Suisse Initiated Coverage on Puma Biotechnology at Outperform, Announces \$69.00 PT

Financial news for PBYI dated on 2016-01-20: Credit Suisse Initiates Coverage on Puma Biotechnology at Outperform, Announces \$69.00 PT

Financial news for PBYI dated on 2015-12-14: Citigroup Upgrades Puma Biotechnology to Buy

Financial news for PBYI dated on 2015-08-27: JP Morgan Initiates Coverage on Puma Biotechnology at Overweight, Announces \$122.00 PT

Financial news for PBYI dated on 2015-05-05: Cowen & Company Downgrades Puma Biotechnology to Market Perform

Financial news for PBYI dated on 2015-01-21: Puma Biotechnology Prices 1M Share Offering @\$190/Share

Financial news for PBYI dated on 2014-11-10: Puma Biotechnology Reports Q3 EPS of \$(0.84) vs \$(1.21) Est

Financial news for PBYI dated on 2014-09-29: Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated NSCLC at ESMO 2014

Financial news for PBYI dated on 2014-08-11: Puma Biotechnology Reports Q2 EPS of \$(1.29) Which May Not Compare \$(0.66) Est

Financial news for PBYI dated on 2014-04-21: CORRECTION: Citigroup Initiates Coverage on Puma Biotechnology at Buy, Announces \$123.00 PT

Financial news for PBYI dated on 2013-12-17: Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations

Financial news for PBYI dated on 2012-11-13: From Earlier: Cowen Initiated Coverage on Puma Biotech at Outperform

Financial news for PBYI dated on 2012-11-13: Benzinga's Top Initiations

Financial news for PBYI dated on 2012-10-24: Puma Biotechnology Closes \$138 Million Public Offering of Common Stock

Financial news for PBYI dated on 2012-10-24: Puma Biotech Closes \$138M Offering of Stock; 8.63M Shares at \$16

Financial news for PBYI dated on 2012-10-22: Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to \$138 Million

Financial news for PBYI dated on 2012-08-24: Stifel Nicolaus Initiates Coverage on Puma Biotechnology at Buy, Announces PT of \$19